keyword
MENU ▼
Read by QxMD icon Read
search

Tau and PET

keyword
https://www.readbyqxmd.com/read/29777006/in-vivo-characterization-and-quantification-of-neurofibrillary-tau-pet-radioligand-18-f-mk-6240-in-humans-from-alzheimer-s-disease-dementia-to-young-controls
#1
Tobey J Betthauser, Karly A Cody, Matthew D Zammit, Dhanabalan Murali, Alexander K Converse, Todd E Barnhart, Charles K Stone, Howard A Rowley, Sterling C Johnson, Bradley T Christian
Tau positron emission tomography (PET) imaging has potential for elucidating changes in the deposition of neuropathological tau aggregates that are occurring during the progression of Alzheimer's disease (AD). This work investigates in vivo kinetics, quantification strategies and imaging characteristics of a novel tau PET radioligand [18 F]MK-6240 in humans. Methods: Fifty-one individuals ranging from cognitively normal young controls to persons with dementia underwent T1-weighted magnetic resonance imaging (MRI), and [11 C]PiB and [18 F]MK-6240 PET imaging...
May 18, 2018: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/29776894/amyloid-pet-in-neurodegenerative-diseases-with-dementia
#2
V Camacho, A Gómez-Grande, P Sopena, D García-Solís, M Gómez Río, C Lorenzo, S Rubí, J Arbizu
Alzheimer's disease (AD) is a neurodegenerative condition characterized by progressive cognitive decline and memory loss, and is the most common form of dementia. Amyloid plaques with neurofibrillary tangles are a neuropathological hallmark of AD that produces synaptic dysfunction and culminates later in neuronal loss. Amyloid PET is a useful, available and non-invasive technique that provides in vivo information about the cortical amyloid burden. In the latest revised criteria for the diagnosis of AD biomarkers were defined and integrated: pathological and diagnostic biomarkers (increased retention on fibrillar amyloid PET or decreased Aβ1-42 and increased T-Tau or P-Tau in CSF) and neurodegeneration or topographical biomarkers (temporoparietal hypometabolism on 18 F-FDG PET and temporal atrophy on MRI)...
May 15, 2018: Revista Española de Medicina Nuclear e Imagen Molecular
https://www.readbyqxmd.com/read/29762152/alzheimer-s-disease-neuroimaging
#3
Jennifer L Whitwell
PURPOSE OF REVIEW: The aim of this study was to discuss the contribution of neuroimaging studies to our understanding of Alzheimer's disease. We now have the capability of measuring both tau and beta-amyloid (Aβ) proteins in the brain, which together with more traditional neuroimaging modalities, has led the field to focus on using neuroimaging to better characterize disease mechanisms underlying Alzheimer's disease. RECENT FINDINGS: Studies have utilized tau and Aβ PET, as well as [18F]fluorodeoxyglucose PET, and structural and functional MRI, to investigate the following topics: phenotypic variability in Alzheimer's disease , including how neuroimaging findings are related to clinical phenotype and age; multimodality analyses to investigate the relationships between different neuroimaging modalities and what that teaches us about disease mechanisms; disease staging by assessing neuroimaging changes in the very earliest phases of the disease in cognitively normal individuals and individuals carrying an autosomal dominant Alzheimer's disease mutation; and influence of other comorbidities and proteins to the disease process...
May 11, 2018: Current Opinion in Neurology
https://www.readbyqxmd.com/read/29761296/neuroimaging-in-lewy-body-dementia
#4
REVIEW
Tayyabah Yousaf, George Dervenoulas, Polytimi-Eleni Valkimadi, Marios Politis
Lewy body dementia (DLB) is a common form of cognitive impairment, accounting for 30% of dementia cases in ages over 65 years. Early diagnosis of DLB has been challenging; particularly in the context of differentiation with Parkinson's disease dementia and other forms of dementias, such as Alzheimer's disease and rapidly progressive dementias. Current practice involves the use of [123 I]FP-CIT-SPECT, [18 F]FDG PET and [123 I]MIBG molecular imaging to support diagnostic procedures. Structural imaging techniques have an essential role for excluding structural causes, which could lead to a DLB-like phenotype, as well as aiding differential diagnosis through illustrating disease-specific patterns of atrophy...
May 14, 2018: Journal of Neurology
https://www.readbyqxmd.com/read/29760644/an-algorithm-for-preclinical-diagnosis-of-alzheimer-s-disease
#5
REVIEW
Tapan K Khan
Almost all Alzheimer's disease (AD) therapeutic trials have failed in recent years. One of the main reasons for failure is due to designing the disease-modifying clinical trials at the advanced stage of the disease when irreversible brain damage has already occurred. Diagnosis of the preclinical stage of AD and therapeutic intervention at this phase, with a perfect target, are key points to slowing the progression of the disease. Various AD biomarkers hold enormous promise for identifying individuals with preclinical AD and predicting the development of AD dementia in the future, but no single AD biomarker has the capability to distinguish the AD preclinical stage...
2018: Frontiers in Neuroscience
https://www.readbyqxmd.com/read/29758940/self-reported-physical-activity-is-associated-with-tau-burden-measured-by-positron-emission-tomography
#6
Belinda M Brown, Stephanie R Rainey-Smith, Vincent Dore, Jeremiah J Peiffer, Samantha C Burnham, Simon M Laws, Kevin Taddei, David Ames, Colin L Masters, Christopher C Rowe, Ralph N Martins, Victor L Villemagne
Numerous animal studies have reported exercise reduces the accumulation of Alzheimer's disease pathology, including amyloid-β (Aβ) and tau. Furthermore, we previously reported a relationship between higher levels of physical activity (PA) and lower brain Aβ burden in a human population. The recent advent of tau positron emission tomography (PET) tracers enables us to extend our investigations into the evaluation of the relationship between PA and brain tau burden. Utilizing data from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study, we have examined the cross-sectional relationship between habitual PA and PET-quantified tau burden...
May 11, 2018: Journal of Alzheimer's Disease: JAD
https://www.readbyqxmd.com/read/29755842/lipopolysaccharide-endotoxemia-induces-amyloid-%C3%AE-and-p-tau-formation-in-the-rat-brain
#7
Li-Ming Wang, Qi Wu, Ryan A Kirk, Kevin P Horn, Ahmed H Ebada Salem, John M Hoffman, Jeffrey T Yap, Joshua A Sonnen, Rheal A Towner, Fernando A Bozza, Rosana S Rodrigues, Kathryn A Morton
Amyloid beta (Aβ) plaques are not specific to Alzheimer's disease and occur with aging and neurodegenerative disorders. Soluble brain Aβ may be neuroprotective and increases in response to neuroinflammation. Sepsis is associated with neurocognitive compromise. The objective was to determine, in a rat endotoxemia model of sepsis, whether neuroinflammation and soluble Aβ production are associated with Aβ plaque and hyperphosphorylated tau deposition in the brain. Male Sprague Dawley rats received a single intraperitoneal injection of 10 mg/kg of lipopolysaccharide endotoxin (LPS)...
2018: American Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/29754276/-718-f-fdg-pet-ct-metabolic-tumor-parameters-and-radiomics-features-in-aggressive-non-hodgkin-s-lymphoma-as-predictors-of-treatment-outcome-and-survival
#8
Aatif Parvez, Noam Tau, Douglas Hussey, Manjula Maganti, Ur Metser
PURPOSE: To determine whether metabolic tumor parameters and radiomic features extracted from 18 F-FDG PET/CT (PET) can predict response to therapy and outcome in patients with aggressive B-cell lymphoma. METHODS: This institutional ethics board-approved retrospective study included 82 patients undergoing PET for aggressive B-cell lymphoma staging. Whole-body metabolic tumor volume (MTV) using various thresholds and tumor radiomic features were assessed on representative tumor sites...
May 12, 2018: Annals of Nuclear Medicine
https://www.readbyqxmd.com/read/29752516/dual-tracer-tau-pet-imaging-reveals-different-molecular-targets-for-11-c-thk5351-and-11-c-pbb3-in-the-alzheimer-brain
#9
Konstantinos Chiotis, Per Stenkrona, Ove Almkvist, Vladimir Stepanov, Daniel Ferreira, Ryosuke Arakawa, Akihiro Takano, Eric Westman, Andrea Varrone, Nobuyuki Okamura, Hitoshi Shimada, Makoto Higuchi, Christer Halldin, Agneta Nordberg
PURPOSE: Several tau PET tracers have been developed, but it remains unclear whether they bind to the same molecular target on the heterogeneous tau pathology. In this study we evaluated the binding of two chemically different tau-specific PET tracers (11 C-THK5351 and 11 C-PBB3) in a head-to-head, in vivo, multimodal design. METHODS: Nine patients with a diagnosis of mild cognitive impairment or probable Alzheimer's disease and cerebrospinal fluid biomarker evidence supportive of the presence of Alzheimer's disease brain pathology were recruited after thorough clinical assessment...
May 12, 2018: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/29749140/increased-uptake-of-av-1451-in-a-subacute-infarction-lesion
#10
Soo Hyun Cho, Hanna Cho, Seongbeom Park, Young Hoon Ryu, Jae Yong Choi, Chul Hyoung Lyoo, Duk L Na, Sang Won Seo, Hee Jin Kim
¹⁸F-AV-1451 is a tau PET ligand that has high affinity for paired helical filament tau. However, various off-target bindings unrelated to tau have also been reported. Herein, we report a case of 83-year-old woman, who showed abnormal uptake of AV-1451 that was shown to be subacute infarction. Clinicians should recognize that increased uptake of AV-1451 may be related to stroke.
June 2018: Yonsei Medical Journal
https://www.readbyqxmd.com/read/29736986/identification-of-alzheimer-s-disease-and-mild-cognitive-impairment-using-multimodal-sparse-hierarchical-extreme-learning-machine
#11
Jongin Kim, Boreom Lee
Different modalities such as structural MRI, FDG-PET, and CSF have complementary information, which is likely to be very useful for diagnosis of AD and MCI. Therefore, it is possible to develop a more effective and accurate AD/MCI automatic diagnosis method by integrating complementary information of different modalities. In this paper, we propose multi-modal sparse hierarchical extreme leaning machine (MSH-ELM). We used volume and mean intensity extracted from 93 regions of interest (ROIs) as features of MRI and FDG-PET, respectively, and used p-tau, t-tau, and Aβ42 as CSF features...
May 7, 2018: Human Brain Mapping
https://www.readbyqxmd.com/read/29728519/first-in-human-pet-study-of-3-novel-tau-radiopharmaceuticals-11-c-ro6924963-11-c-ro6931643-and-18-f-ro6958948
#12
Dean F Wong, Robert Comley, Hiroto Kuwabara, Paul B Rosenberg, Susan M Resnick, Susanne Ostrowitzki, Cristina Vozzi, Frank Boess, Esther Oh, Constantine G Lyketsos, Michael Honer, Luca Gobbi, Gregory Klein, Noble George, Lorena Gapasin, Kelly Kitzmiller, Joshua Roberts, Jeff Sevigny, Ayon Nandi, James R Brasic, Chakradhar Mishra, Madhav Thambisetty, Abhay Moghekar, Anil Mathur, Marilyn Albert, Robert F Dannals, Edilio Borroni
Background: [11 C]RO-963, [11 C]RO-643 and [18 F]RO-948 (previously referred as [11 C]RO6924963, [11 C]RO6931643, and [18 F]RO6958948, respectively) have been reported as promising PET tracers for tau imaging based on in vitro and preclinical PET data (1,2). Here we describe the first human evaluation of these novel radiotracers. Methods: Amyloid PET positive Alzheimer's disease (AD) patients and young healthy subjects (YC) each received two different tau tracers. Dynamic 90 min scans were obtained after bolus injection of [11 C]RO-963, [11 C]RO-643 or [18 F]RO-948...
May 4, 2018: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/29720959/role-of-neuroimaging-as-a-biomarker-for-neurodegenerative-diseases
#13
REVIEW
Soichiro Shimizu, Daisuke Hirose, Hirokuni Hatanaka, Naoto Takenoshita, Yoshitsugu Kaneko, Yusuke Ogawa, Hirofumi Sakurai, Haruo Hanyu
It has recently been recognized that neurodegenerative diseases are caused by common cellular and molecular mechanisms including protein aggregation and inclusion body formation. Each type of neurodegenerative disease is characterized by the specific protein that aggregates. In these days, the pathway involved in protein aggregation has been elucidated. These are leading to approaches toward disease-modifying therapies. Neurodegenerative diseases are fundamentally diagnosed pathologically. Therefore, autopsy is essential for a definitive diagnosis of a neurodegenerative disease...
2018: Frontiers in Neurology
https://www.readbyqxmd.com/read/29716656/large-inter-and-intra-case-variability-of-first-generation-tau-pet-ligand-binding-in-neurodegenerative-dementias
#14
Melissa C Wren, Tammaryn Lashley, Erik Årstad, Kerstin Sander
Imaging of pathological tau with positron emission tomography (PET) has the potential to allow early diagnosis of the dementias and monitoring of disease progression, including assessment of therapeutic interventions, in vivo. The first generation of tau PET tracers, including the carbazole flortaucipir and the 2-arylquinolines of the THK series, are now used in clinical research; however, concerns have been raised about off-target binding and low sensitivity.With the aim to determine the nature of tau pathology depicted by structurally distinct tau ligands we carried out a microscopic neuropathological evaluation in post-mortem human brain tissue of cases with primary and secondary tauopathies...
May 1, 2018: Acta Neuropathologica Communications
https://www.readbyqxmd.com/read/29716618/focs-a-novel-method-for-analyzing-enhancer-and-gene-activity-patterns-infers-an-extensive-enhancer-promoter-map
#15
Tom Aharon Hait, David Amar, Ron Shamir, Ran Elkon
Recent sequencing technologies enable joint quantification of promoters and their enhancer regions, allowing inference of enhancer-promoter links. We show that current enhancer-promoter inference methods produce a high rate of false positive links. We introduce FOCS, a new inference method, and by benchmarking against ChIA-PET, HiChIP, and eQTL data show that it results in lower false discovery rates and at the same time higher inference power. By applying FOCS to 2630 samples taken from ENCODE, Roadmap Epigenomics, FANTOM5, and a new compendium of GRO-seq samples, we provide extensive enhancer-promotor maps ( http://acgt...
May 1, 2018: Genome Biology
https://www.readbyqxmd.com/read/29710718/the-progressive-acalculia-presentation-of-parietal-variant-alzheimer-s-disease
#16
Mario F Mendez, Negar Moheb, Randy E Desarzant, Edmond H Teng
BACKGROUND: Many patients with early-onset Alzheimer's disease (EOAD; age of onset <65 years) have non-amnestic presentations involving language (logopenic primary progressive aphasia, lvPPA), visuospatial abilities (posterior cortical atrophy, PCA), and even asymmetric symptoms consistent with corticobasal syndrome (CBS). An inferior parietal lobule variant of EOAD commonly presents with progressive difficulty with calculations. METHODS: We reviewed 276 EOAD patients for presentations with predominant acalculia...
April 28, 2018: Journal of Alzheimer's Disease: JAD
https://www.readbyqxmd.com/read/29704038/quantitative-evaluation-of-tau-pet-tracers-18-f-thk5351-and-18-f-av-1451-in-alzheimer-s-disease-with-standardized-uptake-value-peak-alignment-suvp-normalization
#17
Jingyun Chen, Yi Li, Elizabeth Pirraglia, Nobuyuki Okamura, Henry Rusinek, Mony J de Leon
PURPOSE: Off-target binding in the reference region is a challenge for recent tau tracers 18 F-AV-1451 and 18 F-THK5351. The conventional standardized uptake value ratio (SUVR) method relies on the average uptake from an unaffected tissue sample, and therefore is susceptible to biases from off-target binding as well as variability among individuals in the reference region. We propose a new method, standardized uptake value peak-alignment (SUVP), to reduce the bias of the SUVR, and improve the quantitative assessment of tau deposition...
April 27, 2018: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/29701788/is-longitudinal-tau-pet-ready-for-use-in-alzheimer-s-disease-clinical-trials
#18
Oskar Hansson, Elizabeth C Mormino
No abstract text is available yet for this article.
May 1, 2018: Brain: a Journal of Neurology
https://www.readbyqxmd.com/read/29698545/the-role-of-molecular-imaging-in-assessing-degenerative-parkinsonism-an-updated-review
#19
Nicolas Nicastro, Valentina Garibotto, Pierre R Burkhard
Diagnosing degenerative forms of parkinsonism still relies on a thorough clinical assessment, which in Parkinson's disease involves the presence of an asymmetric bradykinesia with rest tremor and/or rigidity that respond substantially to levodopa. Conversely, atypical forms, including multiple system atrophy, progressive supranuclear palsy and corticobasal degeneration, exhibit additional features (cerebellar or pyramidal signs, early postural instability), a poor response to dopamine replacement therapy and a bad prognosis...
April 26, 2018: Swiss Medical Weekly
https://www.readbyqxmd.com/read/29686045/subthreshold-amyloid-predicts-tau-deposition-in-aging
#20
Stephanie L Leal, Samuel N Lockhart, Anne Maass, Rachel K Bell, William J Jagust
Current approaches to the early detection of Alzheimer's disease (AD) rely upon classifying individuals as "positive" or "negative" for biomarkers related to the core pathology of beta-amyloid (Aβ). However, the accumulation of Aβ begins slowly, years before biomarkers become abnormal. We used longitudinal [11 C] Pittsburgh Compound B (PIB) PET and neuropsychological assessment to investigate the earliest changes in AD pathology and how it affects memory in cognitively normal older humans (N = 71, mean age 75 yrs, 35% male)...
April 23, 2018: Journal of Neuroscience: the Official Journal of the Society for Neuroscience
keyword
keyword
114281
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"